Drug development in higher-risk myelodysplastic syndromes

被引：0
|
作者：
Sangeetha Venugopal [1 ]
Mikkael A. Sekeres [1 ]
机构：
[1] University of Miami,Division of Hematology, Sylvester Comprehensive Cancer Center
来源：
Blood Cancer Journal | / 14卷 / 1期
关键词：
D O I：
10.1038/s41408-024-01171-y
中图分类号：
学科分类号：
摘要：
引用
下载
收藏
相关论文
共 50 条
  • [31] Management of patients with higher-risk myelodysplastic syndromes after failure of hypomethylating agents: What is on the horizon?
    Bewersdorf, Jan Philipp
    Zeidan, Amer M.
    BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2021, 34 (01)
  • [32] In vitro preclinical assessment of alvocidib in combination with 5-azacytidine in higher-risk myelodysplastic syndromes
    Riabov, V
    Xu, Q.
    Schmitt, N.
    Streuer, A.
    Jann, J. -C
    Wein, A.
    Altrock, E.
    Mehralivand, A.
    Nowak, V
    Weimer, N.
    Oblaender, J.
    Palme, I
    Jawhar, A.
    Weiss, C.
    Metzgeroth, G.
    Foulks, J. M.
    Hofmann, W-K
    Nowak, D.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 99 - 99
  • [33] 5-azacytidine in the treatment of Greek patients with higher-risk myelodysplastic syndromes. An overview
    Zervakis, K.
    Diamantopoulos, P.
    Papadopoulou, V.
    Iliakis, T.
    Mpakarakos, P.
    Kalala, F.
    Giannakopoulou, N.
    Rougkala, N.
    Galanopoulos, A.
    Variami, E.
    Dimitrakopoulou, A.
    Viniou, N.
    LEUKEMIA RESEARCH, 2013, 37 : S159 - S159
  • [34] ACCURACY OF PHYSICIAN ASSESSMENT OF TREATMENT PREFERENCES AND HEALTH STATUS IN PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES
    Caocci, G.
    Voso, M. T.
    Angelucci, E.
    Stauder, R.
    Cottone, F.
    Abel, G.
    Nguyen, K. T. T.
    Platzbecker, U.
    Beyne-Rauzy, O.
    Gaidano, G.
    Invernizzi, R.
    Molica, S.
    Criscuolo, M.
    Breccia, M.
    Luebbert, M.
    Sanpaolo, G.
    Buccisano, F.
    Ricco, A.
    Palumbo, G.
    Niscola, P.
    Zhang, H.
    Fenu, S.
    La Nasa, G.
    Mandelli, F.
    Efficace, F.
    HAEMATOLOGICA, 2015, 100 : 23 - 23
  • [35] Treatment of myelodysplastic syndromes in the era of precision medicine and immunomodulatory drugs: a focus on higher-risk disease
    Razan Mohty
    Rama Al Hamed
    Ali Bazarbachi
    Eolia Brissot
    Arnon Nagler
    Amer Zeidan
    Mohamad Mohty
    Journal of Hematology & Oncology, 15
  • [36] Treatment of myelodysplastic syndromes in the era of precision medicine and immunomodulatory drugs: a focus on higher-risk disease
    Mohty, Razan
    Al Hamed, Rama
    Bazarbachi, Ali
    Brissot, Eolia
    Nagler, Arnon
    Zeidan, Amer
    Mohty, Mohamad
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2022, 15 (01)
  • [37] Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax
    Bazinet, Alexandre
    Desikan, Sai Prasad
    Li, Ziyi
    Rodriguez-Sevilla, Juan Jose
    Venugopal, Sangeetha
    Urrutia, Samuel
    Montalban-Bravo, Guillermo
    Sasaki, Koji
    Chien, Kelly S.
    Hammond, Danielle
    Kanagal-Shamanna, Rashmi
    Ganan-Gomez, Irene
    Kadia, Tapan M.
    Borthakur, Gautam
    Dinardo, Courtney D.
    Daver, Naval G.
    Jabbour, Elias J.
    Ravandi, Farhad
    Kantarjian, Hagop
    Garcia-Manero, Guillermo
    CLINICAL CANCER RESEARCH, 2024, 30 (07) : 1319 - 1326
  • [38] Stopping Higher-Risk Myelodysplastic Syndrome in Its Tracks
    Pollyea, Daniel A.
    Gutman, Jonathan A.
    CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2014, 9 (04) : 421 - 431
  • [39] Stopping Higher-Risk Myelodysplastic Syndrome in Its Tracks
    Daniel A. Pollyea
    Jonathan A. Gutman
    Current Hematologic Malignancy Reports, 2014, 9 : 421 - 431
  • [40] An Update on Higher Risk Myelodysplastic Syndromes
    Hochman, Michael J.
    DeZern, Amy E.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S21 - S25
12345